- Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysisLu, S.; Cho, B. C.; Lee, J-S.; Lee, S-H.; Danchaivijitr, P.; Liu, B.; Alip, A.; Xiong, H.; How, S. H.; Chang, G-C.; Yang, J. C-H.; Yoshioka, H.; Xia, K.; Martinez, M.; Bauml, J. M.; Sethi, S.; Hayashi, H.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trialCho, B. C.; Felip, E.; Spira, A. I.; Girard, N.; Lee, J. S.; Lee, S. H.; Ostapenko, Y. V.; Danchaivijitr, P.; Liu, B.; Alip, A.; Korbenfeld, E. P.; Dias, J.; Sun, T.; Martinez, M.; Bauml, J. M.; Shreeve, M.; Sethi, S.; Knoblauch, R. E.; Hayashi, H.; Lu, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 2
- Efficacy of various types of chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 in-frame insertions.Tang, Haibo; Li, Xiaoning; Cai, Jianhong; Wu, Xiaomin; Zheng, Yating; Huang, MengliVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
会议论文
Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis
7阅读
